An adverse effect is not a substitute for the intended outcome. Someone can experience nausea without a meaningful improvement in the problem being treated. Conversely, absence of nausea does not establish that a medicine lacks activity. These are separate observations.
The controlled RECONNECT studies recorded adverse events as well as efficacy. That separation is deliberate: benefit and tolerability both contribute to a clinical decision. A symptom should not be relabelled as “proof it works” simply because it followed the exposure.
The open-label extension also reported nausea among treatment-related events. Its continuation population was selected from core-trial participants, so those observations do not predict how every new patient will tolerate treatment. A person who discontinued earlier is part of the evidence story even if they are absent from later follow-up.
An individual symptom account should describe severity, persistence, vomiting, ability to maintain fluids and impact on normal activity. “Some nausea” can cover very different experiences. The assessment also needs to know other medicines and exposures rather than assuming every symptom comes from one product.
Persistent or severe nausea deserves contact with the prescribing clinician; inability to maintain fluids or severe accompanying symptoms can require urgent assessment. This article does not recommend adding anti-nausea medicines from forum advice or changing an exposure schedule. Those choices have their own risks and interactions.
There is a further problem when the material is a research-labelled product. A strong sensation cannot establish chemical identity, concentration or manufacturing quality. The same event cannot serve as both a clinical outcome and a laboratory assay.
The useful question is whether the patient's actual goal improved enough to justify the treatment's burdens under medical supervision. That discussion should not be reduced to how noticeable the exposure felt. Trials provide a framework for separating outcomes, while the clinician evaluates the person. Nausea remains a tolerability issue even if another participant online describes it as a sign of potency. A compelling anecdote does not change what the symptom measures.